118 related articles for article (PubMed ID: 36153870)
1. [Prognostic value of translocation t(11;14) in primary light-chain amyloidosis treated with bortezomib-based regimen].
Gao YJ; Shen KN; Feng J; Chang L; Li H; Su W; Cao XX; Zhang L; Zhou DB; Li J
Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2854-2860. PubMed ID: 36153870
[No Abstract] [Full Text] [Related]
2. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
[TBL] [Abstract][Full Text] [Related]
3. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA
Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303
[TBL] [Abstract][Full Text] [Related]
4. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
6. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
Huang X; Wang Q; Chen W; Ren G; Liu Z
Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Venner CP; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Blood; 2012 May; 119(19):4387-90. PubMed ID: 22331187
[TBL] [Abstract][Full Text] [Related]
9. Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime.
Bomsztyk J; Ravichandran S; Khwaja J; Cohen O; Rauf MU; Foard D; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore J; Lachmann H; Mahmood S; Wechalekar AD
Br J Haematol; 2024 Jun; ():. PubMed ID: 38840512
[TBL] [Abstract][Full Text] [Related]
10. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study.
Katoh N; Ueno A; Yoshida T; Tazawa KI; Shimojima Y; Gono T; Sekijima Y; Matsuda M; Ikeda SI
Int J Hematol; 2017 Mar; 105(3):341-348. PubMed ID: 27832515
[TBL] [Abstract][Full Text] [Related]
13. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
[TBL] [Abstract][Full Text] [Related]
14. Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience.
Riva M; Berno T; Cipriani A; Altinier S; Fedrigo M; Noventa F; Adami F
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e970-e974. PubMed ID: 34489209
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
16. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.
Muchtar E; Dispenzieri A; Kumar SK; Ketterling RP; Dingli D; Lacy MQ; Buadi FK; Hayman SR; Kapoor P; Leung N; Chakraborty R; Gonsalves W; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Gertz MA
Leukemia; 2017 Jul; 31(7):1562-1569. PubMed ID: 27904139
[TBL] [Abstract][Full Text] [Related]
17. [Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone].
Zhao Q; Wang L; Song P; Li F; Zhou X; Yu Y; An Z; Wang X; Zhai Y
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):283-7. PubMed ID: 27093989
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.
Sperry BW; Ikram A; Hachamovitch R; Valent J; Vranian MN; Phelan D; Hanna M
J Am Coll Cardiol; 2016 Jun; 67(25):2941-8. PubMed ID: 27339491
[TBL] [Abstract][Full Text] [Related]
19. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
20. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]